BACKGROUND: The BENEFIT study examined interferon beta (IFNB)-1b treatment in patients with clinically isolated syndrome (CIS) and > or = 2 clinically silent brain MRI lesions. METHODS:Subgroups of 468 patients (IFNB-1b: n = 292; placebo: n = 176) were created for demographics, clinical, laboratory, and MRI findings at onset. The 'natural' risk of clinically definite MS (CDMS) over 2 years was estimated by Kaplan Meier statistics in placebo-treated patients; the IFNB-1b treatment effect was analysed by Cox proportional hazards regression. RESULTS: The risk of CDMS was increased in placebo-treated patients (overall 45 %) if they were younger (< 30 years: 60%), were cerebrospinal fluid (CSF)-positive (49 %), or had received steroid treatment (48 %). MRI parameters implied a higher risk in placebo-treated patients with > or = 9 T2-lesions (48%) or > or = 1 gadolinium (Gd)-enhancing lesions (52 %). The CDMS risk was highest (75 %) in placebo-treated patients with monofocal disease onset displaying MRI disease activity (> or = 1 Gd-lesion) and dissemination (> or = 9 T2-lesions). Treatment effects were significant across almost all subgroups including patients with less disease dissemination/activity at onset (monofocal: 55%; < 9 T2-lesions: 60%; no Gd-lesions: 57%) and patients without steroid treatment for the CIS (62 %). Monofocal patients had greater treatment effects if they had > or = 9 T2-lesions (61 %), Gd-lesions (58 %), or both (65 %). CONCLUSIONS: This study confirms the impact of age of onset, CSF and MRI findings on risk of conversion from CIS to CDMS. IFNB-1b treatment effect was robust across the study population including patients without MRI disease activity and less clinical or MRI disease dissemination at onset and patients not receiving steroids for the CIS.
RCT Entities:
BACKGROUND: The BENEFIT study examined interferon beta (IFNB)-1b treatment in patients with clinically isolated syndrome (CIS) and > or = 2 clinically silent brain MRI lesions. METHODS: Subgroups of 468 patients (IFNB-1b: n = 292; placebo: n = 176) were created for demographics, clinical, laboratory, and MRI findings at onset. The 'natural' risk of clinically definite MS (CDMS) over 2 years was estimated by Kaplan Meier statistics in placebo-treated patients; the IFNB-1b treatment effect was analysed by Cox proportional hazards regression. RESULTS: The risk of CDMS was increased in placebo-treated patients (overall 45 %) if they were younger (< 30 years: 60%), were cerebrospinal fluid (CSF)-positive (49 %), or had received steroid treatment (48 %). MRI parameters implied a higher risk in placebo-treated patients with > or = 9 T2-lesions (48%) or > or = 1 gadolinium (Gd)-enhancing lesions (52 %). The CDMS risk was highest (75 %) in placebo-treated patients with monofocal disease onset displaying MRI disease activity (> or = 1 Gd-lesion) and dissemination (> or = 9 T2-lesions). Treatment effects were significant across almost all subgroups including patients with less disease dissemination/activity at onset (monofocal: 55%; < 9 T2-lesions: 60%; no Gd-lesions: 57%) and patients without steroid treatment for the CIS (62 %). Monofocal patients had greater treatment effects if they had > or = 9 T2-lesions (61 %), Gd-lesions (58 %), or both (65 %). CONCLUSIONS: This study confirms the impact of age of onset, CSF and MRI findings on risk of conversion from CIS to CDMS. IFNB-1b treatment effect was robust across the study population including patients without MRI disease activity and less clinical or MRI disease dissemination at onset and patients not receiving steroids for the CIS.
Authors: L D Jacobs; R W Beck; J H Simon; R P Kinkel; C M Brownscheidle; T J Murray; N A Simonian; P J Slasor; A W Sandrock Journal: N Engl J Med Date: 2000-09-28 Impact factor: 91.245
Authors: D K B Li; U Held; J Petkau; M Daumer; F Barkhof; F Fazekas; J A Frank; L Kappos; D H Miller; J H Simon; J S Wolinsky; M Filippi Journal: Neurology Date: 2006-05-09 Impact factor: 9.910
Authors: R W Beck; P A Cleary; M M Anderson; J L Keltner; W T Shults; D I Kaufman; E G Buckley; J J Corbett; M J Kupersmith; N R Miller Journal: N Engl J Med Date: 1992-02-27 Impact factor: 91.245
Authors: L Kappos; C H Polman; M S Freedman; G Edan; H P Hartung; D H Miller; X Montalban; F Barkhof; L Bauer; P Jakobs; C Pohl; R Sandbrink Journal: Neurology Date: 2006-08-16 Impact factor: 9.910
Authors: O Fernández; V Fernández; T Arbizu; G Izquierdo; I Bosca; R Arroyo; J A García Merino; E de Ramón Journal: J Neurol Date: 2010-04-10 Impact factor: 4.849
Authors: Maria Trojano; Mar Tintore; Xavier Montalban; Jan Hillert; Tomas Kalincik; Pietro Iaffaldano; Tim Spelman; Maria Pia Sormani; Helmut Butzkueven Journal: Nat Rev Neurol Date: 2017-01-13 Impact factor: 42.937
Authors: Jaume Sastre-Garriga; M Tintoré; C Nos; C Tur; J Río; N Téllez; J Castilló; A Horga; H Perkal; M Comabella; A Rovira; X Montalban Journal: J Neurol Date: 2009-11-28 Impact factor: 4.849
Authors: Kerstin Bendfeldt; Bernd Taschler; Laura Gaetano; Philip Madoerin; Pascal Kuster; Nicole Mueller-Lenke; Michael Amann; Hugo Vrenken; Viktor Wottschel; Frederik Barkhof; Stefan Borgwardt; Stefan Klöppel; Eva-Maria Wicklein; Ludwig Kappos; Gilles Edan; Mark S Freedman; Xavier Montalbán; Hans-Peter Hartung; Christoph Pohl; Rupert Sandbrink; Till Sprenger; Ernst-Wilhelm Radue; Jens Wuerfel; Thomas E Nichols Journal: Brain Imaging Behav Date: 2019-10 Impact factor: 3.978
Authors: Jessica M Nielsen; Christoph Pohl; Chris H Polman; Frederik Barkhof; Mark S Freedman; Gilles Edan; David H Miller; Lars Bauer; Rupert Sandbrink; Ludwig Kappos; Bernard M J Uitdehaag Journal: BMC Neurol Date: 2009-05-20 Impact factor: 2.474